The Genentech BioOncology® Co-pay Assistance Program for VENCLEXTA + rituximab
Talk to your patients about their financial concerns related to their prescribed Genentech treatment. Eligible patients pay $5 for their prescribed Genentech BioOncology® product(s)* with the Genentech BioOncology® Co-pay Assistance Program.
*For FDA-approved Genentech BioOncology® single and combination therapies.
The VENCLEXTA SureStart® Program
If your patient faces a coverage delay, the VENCLEXTA SureStart™ Program can help your patient start his or her VENCLEXTA therapy while waiting for a coverage decision.
Other eligibility criteria and requirements may apply. To get started, call (888) 249-4981 or submit the completed Statement of Medical Necessity (SMN), Patient Authorization, and Notice of Release of Information (PAN) to Access Solutions. These forms can be downloaded at Genentech-Access.com/VENCLEXTA.
VENCLEXTA Access Solutions provides reliable, effective access and reimbursement services to assist your CLL/SLL patients and practice.
We can help you address the needs of each patient’s coverage scenario:
*Other eligibility criteria and requirements may apply.
BioOncology® logo is a registered trademark of Genentech, Inc.
The Access Solutions logo is a registered trademark of Genentech, Inc.